Navigation Links
Lorus Therapeutics Strengthens Its Senior Management Team Through Internal Promotions
Date:5/5/2008

d are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions that, while considered reasonable by us are inherently subject to significant business, economic, competitive, political and social uncertainties and contingencies. Many factors could cause our actual results, performance, achievements or the transactions described in this press release to be materially different from any future results, performance, achievements or transactions described in this press release, if at all, that may be expressed or implied by such forward-looking statements, including, among others: the progress of negotiations; our ability to obtain regulatory, security holder and other approvals; our ability to obtain the capital required for research and operations; the inherent risks in early stage drug development including demonstrating efficacy; development time/cost and the regulatory approval process; the progress of our clinical trials; our ability to find and enter into agreements with potential partners; our ability to attract and retain key personnel; changing market conditions; and other risks detailed from time-to-time in our ongoing quarterly filings, annual information forms, annual reports and annual filings with Canadian securities regulators and the United States Securities and Exchange Commission.

Should one or more of these risks or uncertainties materialize, or should the assumptions set out in the section entitled "Risk Factors" in our filings with Canadian securities regulators and the United States Securities and Exchange Commission underlying those forward-looking statements prove incorrect, actual results may vary materially from those described herein. These forward-looking statements are made as of the date of this press release and we do not intend, and do not assume any obligation, to update these forward-looking statements, except as required by law. We cannot assure you that such statements will prove t
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
2. Lorus Therapeutics Appoints Peter Korth as Chief Financial Officer
3. Lorus Therapeutics Announces Exclusive Multinational License Agreement with Zoticon Bioventures for Virulizin(R)
4. Lorus Therapeutics presents new findings for the anticancer drugs LOR-253 and LOR-2040
5. Lorus initiates development program exploring novel route of administration for LOR-2040
6. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
7. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
8. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
9. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
10. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
11. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... “Preparative & Process Chromatography Market by ... Solvents, Buffers, Valves, Guages, Seals), Accessories, Services, End ... to 2019” provides a detailed overview of the ... and strategies impacting the preparative and process chromatography ... the revenue and share analysis. , Full ...
(Date:12/24/2014)... Island, New York (PRWEB) December 23, 2014 ... and the Long Island Affiliate of ITRA Global, the national ... slow but steady recovery. This is evidenced by the ... the strong stock market. Low energy costs have held ... The only negative is the housing market remaining soft. ...
(Date:12/24/2014)... 2014 China Biologic Products, Inc. (NASDAQ: ... fully integrated plasma-based biopharmaceutical company in ... subsidiary, Shandong Taibang Biological Products Co. Ltd., has ... China Food and Drug Administration (the "CFDA") for ... disclosed in the Company,s public filings, the CFDA ...
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014 ... pilot study of mazindol in children with attention deficit/hyperactivity ... in December 2014 . The paper, ... with attention deficit/hyperactivity disorder" ( Konofal et al, ... 1;8:2321-2332. eCollection 2014 ) shows that mazindol might ...
Breaking Biology Technology:Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4ITRA Global Reports Long Island Is Out of Sync With The National Office Market 2ITRA Global Reports Long Island Is Out of Sync With The National Office Market 3China Biologic Receives GMP Certification for New Coagulation Factor Facility 2China Biologic Receives GMP Certification for New Coagulation Factor Facility 3Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3
... LifeQuest World Corporation,(OTC Bulletin Board: LQWC) is ... work, ImmunXT, their Immune System enhancement supplement, has,been ... as of March 2008.,ImmunXT has been proclaimed as ... ImmunXT (US Patent #7,205,284 B2),is a bio-active Micro-algae ...
... (OTC Bulletin Board: GNTA) announced today that it ... (FINRA, formerly,the NASD) has cleared a market maker,s ... the Over-the-Counter Bulletin Board (OTCBB). As a,result, the ... Company,s,common stock will begin on Wednesday, May 7, ...
... Calif., May 6 Kosan Biosciences,Incorporated (Nasdaq: ... Vice,President, Corporate Communications, will present at the Leerink ... the Grand Hyatt Hotel on,Friday, May 9, 2008 ... the presentation,can be accessed through http://www.wsw.com/webcast/leerink15/kosn/ ., ...
Cached Biology Technology:LifeQuest World Launches Immune System Boosting Supplement to the North American Market 2Genta Announces Transfer of its Common Stock to the OTC Bulletin Board 2Genta Announces Transfer of its Common Stock to the OTC Bulletin Board 3Kosan Biosciences to Present at the Leerink Swann Solid Tumors Roundtable Conference 2
(Date:12/11/2014)... --Research and Markets , ... ) has announced the addition of the ... their offering. One major trend ... multimodal biometric systems. Multimodal biometric systems utilize more ... and identification purposes. This helps to reduce the ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader ... is seeing a staggering demand from its licensees for ... Company revealed, is not solely coming from fitness and ... well. "A wearable is only as useful ... accuracy is the ultimate driver in long-term mass consumer ...
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... gene therapy reversed course of disease in mouse modelsIn ... disease, scientists were able to reverse the rodents' memory ... is crucial for the development of Alzheimer's disease. , ... that stopping the synthesis of a protein that is ...
... Billions of people tuned into recent Live 8 concert ... the altruistic cause spearheaded by former Boomtown Rat, Sir ... of us look out for each other, while others ... natural selection has designed individuals to behave selfishishly; selfish ...
... medically important fungus, causing potentially life-threatening infections in patients ... cause of respiratory allergy, and it is implicated in ... to lack the ability to reproduce sexually, but new ... the fungus has a number of characteristics of sex. ...
Cached Biology News:Targeting a key enzyme with gene therapy reversed course of Alzheimer's disease in mouse models 2Targeting a key enzyme with gene therapy reversed course of Alzheimer's disease in mouse models 3Helping in a selfish world 2Secret sex life of killer fungus? 2
Recombinant Rat Leptin, CF...
2,4,6-Trinitrophenyl hapten is conjugated to Bovine Gamma Globulin (BGG) through lysine by amide bonds....
... 25 mL pipets ,Angled acrylic pipet rack offers ... or round pipet cans. Constructed of 6 mm (1/4 ... W x 76 mm H x 289 mm D ... 89 mm W x 406 mm H x 292 ...
... Contact Printing Kit contains choice of PDMS ... of 100 / 200 micron squares or ... um x 10 mm lines, 3 PDMS ... or 60 nm and pitch of 400 ...
Biology Products: